COIOSDeep risk insights through multi-disciplinary research across the globe
a view of a city with a bridge in the foreground
Item new Peer-reviewed Added

Genomic testing reached 38% of Ohio Medicaid women with ER-positive early breast cancer

Among 1,988 Ohio Medicaid patients with early ER-positive breast cancer, 37.8% received Oncotype DX or MammaPrint within six months, with receipt lower for regional than localised disease (aOR 0.35).

A retrospective cohort linked the Ohio cancer registry to Medicaid claims for 1,988 patients aged 18 to 65 with non-metastatic ER-positive, HER2-negative breast cancer. Molecular profiling within six months of diagnosis was recorded for 752 of them, 37.8%. Receipt was lower for regional than localised disease (aOR 0.35) and for Black than White women (aOR 0.72).

Why it is interesting: Testing that informs precision oncology reached under two in five, and varied by stage and race.

Source
JCO Oncology Practice, 22 September 2026
Paper
Missed Precision: Gaps in Molecular Profiling Among Medicaid Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Authors
Lal T, Vu L, Abou Zeidane R, Pisano C, Shoag J, Hoehn RS et al.
DOI
10.1200/op-26-00255
Type
Peer-reviewed article
Design
Retrospective cohort, Ohio cancer registry linked to Medicaid claims, n=1,988 diagnosed 2016-2020
Verdict
New finding
Driver
Cancer
Driver
Health systems and access
Driver
Health systems and access

Other drivers in Health today